Price
CHART BY
Frequently asked questions
What is Halozyme's market capitalization?
The market capitalization of Halozyme is $5.97B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Halozyme's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Halozyme is 15.54. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Halozyme?
Halozyme's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $3.022. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Halozyme's stock?
Currently, 10 analysts cover Halozyme's stock, with a consensus target price of $64.00. Analyst ratings provide insights into the stock's expected performance.
What is Halozyme's revenue over the trailing twelve months?
Over the trailing twelve months, Halozyme reported a revenue of $947.36M.
What is the EBITDA for Halozyme?
Halozyme's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $558.63M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Halozyme?
Halozyme has a free cash flow of $392.71M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Halozyme have, and what sector and industry does it belong to?
Halozyme employs approximately 373 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Halozyme's shares?
The free float of Halozyme is 125.88M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $5.97B
- EPS (TTM)
- $3.022
- Free Float
- 125.88M
- P/E ratio (TTM)
- 15.54
- Revenue (TTM)
- $947.36M
- EBITDA (TTM)
- $558.63M
- Free Cashflow (TTM)
- $392.71M
Pricing
- 1D span
- $46.90$48.15
- 52W span
- $33.16$65.53
Analyst Ratings
The price target is $64.00 and the stock is covered by 10 analysts.
Buy
6
Hold
4
Sell
0
Information
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
- Employees
- 373
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US40637H1095
- Primary Ticker
- HALO